169 related articles for article (PubMed ID: 2533144)
21. [Effect of GnRH analogues pre-treatment on myomectomy outcomes in reproductive age women].
Hudecek R; Ivanová Z; Smerdová M; Pánková S; Krajcovicová R
Ceska Gynekol; 2012 Apr; 77(2):109-17. PubMed ID: 22702067
[TBL] [Abstract][Full Text] [Related]
22. Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids.
West CP; Lumsden MA; Hillier H; Sweeting V; Baird DT
Hum Reprod; 1992 Mar; 7(3):328-32. PubMed ID: 1534089
[TBL] [Abstract][Full Text] [Related]
23. Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase.
Healy DL; Lawson SR; Abbott M; Baird DT; Fraser HM
J Clin Endocrinol Metab; 1986 Sep; 63(3):619-25. PubMed ID: 3090092
[TBL] [Abstract][Full Text] [Related]
24. Monthly implant of luteinizing hormone-releasing hormone agonist: a practical therapeutic approach for sex-steroid dependent gynecologic diseases.
Lemay A
Fertil Steril; 1987 Jul; 48(1):10-2. PubMed ID: 2954859
[No Abstract] [Full Text] [Related]
25. The management of leiomyoma uteri by GnRH analogues.
Giorgino FL; Cetera C
Clin Exp Obstet Gynecol; 1991; 18(2):137-43. PubMed ID: 1833095
[TBL] [Abstract][Full Text] [Related]
26. Maintained reduction of uterine leiomyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study.
Maheux R; Lemay A; Blanchet P; Friede J; Pratt X
Hum Reprod; 1991 Apr; 6(4):500-5. PubMed ID: 1655823
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical localization of epidermal growth factor receptor in leiomyomas from women treated with goserelin depot.
Leone M; Cucuccio S; Venturini PL; Valenzano-Menada M; Messeni Leone M; De Cecco L
Horm Metab Res; 1991 Sep; 23(9):442-5. PubMed ID: 1835956
[TBL] [Abstract][Full Text] [Related]
28. Clinical predictors for buserelin acetate treatment of uterine fibroids: a prospective study of 40 women.
Vollenhoven BJ; Shekleton P; McDonald J; Healy DL
Fertil Steril; 1990 Dec; 54(6):1032-8. PubMed ID: 2123160
[TBL] [Abstract][Full Text] [Related]
29. Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist Buserelin.
Matta WH; Stabile I; Shaw RW; Campbell S
Fertil Steril; 1988 Jun; 49(6):1083-5. PubMed ID: 2967195
[TBL] [Abstract][Full Text] [Related]
30. The place of Zoladex in deferred surgery for uterine fibroids. Zoladex Myoma Study Group.
Gerris J; Degueldre M; Peters AA; Romao F; Stjernquist M; al-Taher H
Horm Res; 1996; 45(6):279-84. PubMed ID: 8793522
[TBL] [Abstract][Full Text] [Related]
31. Role of goserelin-depot in the clinical management of uterine fibroids.
Cagnacci A; Paoletti AM; Soldani R; Angiolucci M; Arangino S; Falqui A; Melis GB
Clin Exp Obstet Gynecol; 1994; 21(4):263-5. PubMed ID: 7994879
[TBL] [Abstract][Full Text] [Related]
32. Management of submucous uterine fibroid with buserelin, gemeprost and hysteroscopic resection.
Lawrence AS; Healy DL; Hill D; Paterson PJ
Med J Aust; 1991 Feb; 154(4):280-2. PubMed ID: 1899715
[TBL] [Abstract][Full Text] [Related]
33. Infarcted intramural uterine leiomyomata during buserelin acetate treatment.
Chang MY; Tsai FB; Soong YK
Changgeng Yi Xue Za Zhi; 1993 Jun; 16(2):129-32. PubMed ID: 8339156
[TBL] [Abstract][Full Text] [Related]
34. Presurgical treatment of uterine fibroids by using gonadotropin-releasing hormone agonists.
Falsetti L; Mazzani MD; Rubessa S; Ruggeri C
Acta Eur Fertil; 1992; 23(1):29-32. PubMed ID: 1293897
[TBL] [Abstract][Full Text] [Related]
35. Fibroids: overview of current and future treatment options.
Benagiano G; Morini A; Primiero FM
Br J Obstet Gynaecol; 1992 Feb; 99 Suppl 7():18-22. PubMed ID: 1554684
[No Abstract] [Full Text] [Related]
36. Cornual fibroids: a conservative approach to restoring tubal patency using a gonadotropin-releasing hormone agonist (goserelin) with successful pregnancy.
Gardner RL; Shaw RW
Fertil Steril; 1989 Aug; 52(2):332-4. PubMed ID: 2526755
[TBL] [Abstract][Full Text] [Related]
37. Treatment with GnRH agonists before myomectomy and the risk of short-term myoma recurrence.
Fedele L; Vercellini P; Bianchi S; Brioschi D; Dorta M
Br J Obstet Gynaecol; 1990 May; 97(5):393-6. PubMed ID: 2115379
[TBL] [Abstract][Full Text] [Related]
38. Use of GnRH depot analogue in the treatment of uterine fibroids.
Auber G; Ricci G; Barciulli F; Pregazzi R; D'Ancona RL; Toffoletti FG
Acta Eur Fertil; 1990; 21(4):185-9. PubMed ID: 2150737
[TBL] [Abstract][Full Text] [Related]
39. [Myomectomy performed after Zoladex preparation with subsequent repair of the uterine wall via a balloon catheter in the uterine cavity].
Nikolov A; Raĭcheva R; Maĭnkhard K
Akush Ginekol (Sofiia); 1998; 37(1):55-7. PubMed ID: 9770805
[No Abstract] [Full Text] [Related]
40. Effects of gonadotrophin-releasing hormone agonist on uterine fibroids and bone density.
Bianchi G; Costantini S; Anserini P; Rovetta G; Monteforte P; Menada MV; Fagà L; De Cecco L
Maturitas; 1989 Sep; 11(3):179-85. PubMed ID: 2512467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
